Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Endocrine
Published in: Endocrine 2/2017

01-05-2017 | Research Letter

Circulating periostin in patients with nonalcoholic fatty liver disease

Authors: Stergios A. Polyzos, Jannis Kountouras, Athanasios D. Anastasilakis, Athanasios Papatheodorou, Panagiotis Kokkoris, Evangelos Terpos

Published in: Endocrine | Issue 2/2017

Login to get access

Excerpt

Nonalcoholic fatty liver disease (NAFLD), the hepatic manifestation of the metabolic syndrome, ranges from nonalcoholic simple steatosis (SS) to nonalcoholic steatohepatitis (NASH), characterized by inflammation and/or fibrosis, and to NASH-related cirrhosis and hepatocellular carcinoma [1]. Liver biopsy still is regarded as the reference for the diagnosis of NAFLD, although identification of noninvasive biomarkers is a field of intense research, expected to help both clinical trials and clinical practice, which are to date impaired due to the need of paired biopsies [2]. …
Literature
1.
S.A. Polyzos, J. Kountouras, C. Zavos, Nonalcoholic fatty liver disease: The pathogenetic roles of insulin resistance and adipocytokines. Curr. Mol. Med. 72, 299–314 (2009)CrossRef
2.
S.A. Polyzos, C.S. Mantzoros, Necessity for timely noninvasive diagnosis of nonalcoholic fatty liver disease. Metabolism 63, 161–167 (2014)CrossRef
3.
A.Y. Liu, H. Zheng, G. Ouyang, Periostin, a multifunctional matricellular protein in inflammatory and tumor microenvironments. Matrix. Biol. 37, 150–156 (2014)CrossRef
4.
S.A. Polyzos, A.D. Anastasilakis, Periostin on the road to nonalcoholic fatty liver disease. Endocrine 51, 4–6 (2016)CrossRef
5.
J.Z. Zhu, H.T. Zhu, Y.N. Dai, C.X. Li, Z.Y. Fang, D.J. Zhao, X.Y. Wan, Y.M. Wang, F. Wang, C.H. Yu, Y.M. Li, Serum periostin is a potential biomarker for non-alcoholic fatty liver disease: a case-control study. Endocrine 51, 91–100 (2016)CrossRef
6.
S. Polyzos, J. Kountouras, A. Papatheodorou, E. Katsiki, K. Patsiaoura, E. Zafeiriadou, C. Zavos, E. Papadopoulou, E. Terpos, Adipocytokines and cytokeratin-18 in patients with nonalcoholic fatty liver disease—Introduction of CHA index. Ann. Hepatol. 12, 749–757 (2013)CrossRef
7.
D.E. Kleiner, E.M. Brunt, N.M. Van, C. Behling, M.J. Contos, O.W. Cummings, L.D. Ferrell, Y.C. Liu, M.S. Torbenson, A. Unalp-Arida, M. Yeh, A.J. McCullough, A.J. Sanyal, Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology 41, 1313–1321 (2005)CrossRef
8.
S.A. Polyzos, A.D. Anastasilakis, J. Kountouras, P. Makras, A. Papatheodorou, P. Kokkoris, G.T. Sakellariou, E. Terpos, Circulating sclerostin and Dickkopf-1 levels in patients with nonalcoholic fatty liver disease. J. Bone. Miner. Metab. 34, 447–456 (2016)CrossRef
9.
T. Wu, S. Wu, G. Ouyang, Periostin: A new extracellular regulator of obesity-induced hepatosteatosis. Cell Metab. 20, 562–564 (2014)CrossRef
10.
Y. Li, S. Wu, S. Xiong, G. Ouyang, Deficiency of periostin protects mice against methionine-choline-deficient diet-induced non-alcoholic steatohepatitis. J. Hepatol. 62, 495–497 (2015)CrossRef
11.
Y. Huang, W. Liu, H. Xiao, A. Maitikabili, Q. Lin, T. Wu, Z. Huang, F. Liu, Q. Luo, G. Ouyang, Matricellular protein periostin contributes to hepatic inflammation and fibrosis. Am. J. Pathol. 185, 786–797 (2015)CrossRef
Metadata
Title
Circulating periostin in patients with nonalcoholic fatty liver disease
Authors
Stergios A. Polyzos
Jannis Kountouras
Athanasios D. Anastasilakis
Athanasios Papatheodorou
Panagiotis Kokkoris
Evangelos Terpos
Publication date
01-05-2017
Publisher
Springer US
Published in
Endocrine / Issue 2/2017
Print ISSN: 1355-008X
Electronic ISSN: 1559-0100
DOI
https://doi.org/10.1007/s12020-016-1144-x

Other articles of this Issue 2/2017

Endocrine 2/2017 Go to the issue

Original Article

The expression of monocarboxylate transporters in thyroid carcinoma can be associated with the morphological features of BRAF V600E mutation

Original Article

High dose of radioactive iodine per se has no effect on glucose metabolism in thyroidectomized rats

Mini Review

Effect of cilostazol in treating diabetes-associated microvascular complications

Original Article

Low-after-high glucose down-regulated Cx43 in H9c2 cells by autophagy activation via cross-regulation by the PI3K/Akt/mTOR and MEK/ERK1/2 signal pathways

Original Article

Presence of headache and headache types in patients with tumors of the sellar region—can surgery solve the problem? Results of a prospective single center study

Letter to the Editor

Depression and diabetes mellitus

ACC 2024 Congress Coverage

Heart Failure Video

Year in Review: Heart failure and cardiomyopathies

Watch now

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits